Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SEMAFO
Indianapolis, Indiana, United Statessemaforepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Semafore Pharmaceuticals was a clinical-stage biotechnology company focused on the discovery and development of small molecule signal transduction inhibitors targeting the PI3K/PTEN pathway. The company's lead candidate, SF1126, was a first-in-class pan-PI3K/mTOR inhibitor designed as a peptidic prodrug to enhance solubility and tumor-specific delivery via RGD-recognizing integrins. Semafore's pipeline also included SF2626, a dual MEK/PI3K inhibitor, and early-stage PTEN modulators. Although the company ceased operations, its lead assets were later licensed to SignalRx Pharmaceuticals for further development.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptide-drug conjugate
- Industry
- Biotech
02
Partnerships
Indiana's 21st Century Research and Technology FundMultiple Myeloma Research FoundationCancer Treatment Research Foundation
Beyond the preview
Go deeper on SEMAFO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEMAFO.